Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17Se2lEPTB;NT64OlY3KM7:TR?= MWLTRW5ITVJ?
DOHH-2 M2LCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTtdHVKSzVyPUmuN|U3QDlizszN M1TxS3NCVkeHUh?=
no-10 M3Lsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3LTWM2OD17LkmwN|kh|ryP MWnTRW5ITVJ?
LS-513 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLJTWM2OD1zMT6zOVQ4KM7:TR?= MkfzV2FPT0WU
ALL-PO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTZ[GN1UUN3ME2xNU44PzN2IN88US=> NYjjbY1bW0GQR1XS
8-MG-BA MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rnSGlEPTB;MUOuNVEzOyEQvF2= M{O3XXNCVkeHUh?=
RPMI-8402 NFfyNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHObnJKSzVyPUG1Mlg2OzdizszN M1n6fHNCVkeHUh?=
EoL-1-cell MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF6LkW5OFgh|ryP NXnKWm9wW0GQR1XS
NALM-6 NXTo[2tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfNWZZKSzVyPUG5MlAyPjdizszN M{L4d3NCVkeHUh?=
DEL MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL4e|RwUUN3ME2yNE4yPDdzIN88US=> NWrvPVdNW0GQR1XS
SR M3vTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rye2lEPTB;MkOuOlcyPSEQvF2= NGnISJJUSU6JRWK=
697 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17ReWlEPTB;Mk[uOlE2PSEQvF2= MYrTRW5ITVJ?
COLO-829 NVLIOHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorQTWM2OD1{Nj64OFg{KM7:TR?= Mn7BV2FPT0WU
EVSA-T MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TUSGlEPTB;MkeuOVU3OSEQvF2= MWHTRW5ITVJ?
ATN-1 M2XkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojhTWM2OD1|MT6yN|I6KM7:TR?= Mne4V2FPT0WU
L-363 NYnQcXRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNzLke0OlEh|ryP NHvxb|lUSU6JRWK=
LAMA-84 NFnhTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDZPWJsUUN3ME2zNk42OjFzIN88US=> MmK3V2FPT0WU
NOS-1 M4XSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN2LkK5OVYh|ryP NXHGR2gzW0GQR1XS
BB30-HNC NWX1PHdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PidmlEPTB;M{SuN|MxPiEQvF2= MVHTRW5ITVJ?
BC-1 M3rOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPsTJhMUUN3ME2zO{46PzR4IN88US=> MU\TRW5ITVJ?
IST-SL2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;OTWM2OD1|OD6yNlQh|ryP M{DGdHNCVkeHUh?=
D-392MG NF\CW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jPTGlEPTB;NECuNlIyPSEQvF2= MYHTRW5ITVJ?
no-11 NFvXTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PpbWlEPTB;NECuOVUzOSEQvF2= NFvqWmNUSU6JRWK=
LC4-1 NVPURXFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRyLki3NVYh|ryP NHHifFRUSU6JRWK=
A388 NWTvfoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPRTWM2OD12Mj61PFQ5KM7:TR?= NWjxUlZpW0GQR1XS
NTERA-S-cl-D1 M2DmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfme4hKSzVyPUSyMlcxPzRizszN MYHTRW5ITVJ?
CESS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PlRWlEPTB;NESuNlI{OiEQvF2= MXTTRW5ITVJ?
RS4-11 NXXlW3FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX34WIF1UUN3ME20PU4xQTN6IN88US=> M37ofHNCVkeHUh?=
MS-1 M4HLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLqeFdQUUN3ME21NE46OzVzIN88US=> NET4e4VUSU6JRWK=
CTV-1 NUXGVYdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTVzLkC3OEDPxE1? NXjWdZN1W0GQR1XS
D-502MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XvRmlEPTB;NUGuOlI4OSEQvF2= NYfudJYxW0GQR1XS
ML-2 NWL4RXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjl[ZhwUUN3ME21Nk46OTl3IN88US=> NIT3SXdUSU6JRWK=
SK-NEP-1 NULRXWtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD13Mz6zPVI{KM7:TR?= NYK2XpB6W0GQR1XS
LOXIMVI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPhTWM2OD13Mz61PFg1KM7:TR?= M1;DU3NCVkeHUh?=
DJM-1 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S4O2lEPTB;NU[uN|M6OSEQvF2= NXT6eW5YW0GQR1XS
GI-1 M1jt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;OVol6UUN3ME21Ok43OTR7IN88US=> M3zZTXNCVkeHUh?=
IST-MES1 M2PuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPWcWU{UUN3ME22NE42PDl|IN88US=> MWXTRW5ITVJ?
MV-4-11 NIThS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjoTWM2OD14MD62OVM5KM7:TR?= M{Xu[HNCVkeHUh?=
OVCAR-4 NEH6c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLkUpZKSzVyPU[zMlU3PTdizszN MUPTRW5ITVJ?
KE-37 NHq4coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn76TWM2OD14Nj6yOlY5KM7:TR?= M1O1fHNCVkeHUh?=
D-542MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK5TWM2OD14OD60NVM2KM7:TR?= NGrybVlUSU6JRWK=
MHH-PREB-1 NXH4S4czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPBVWxKSzVyPUeyMlg1PDFizszN M3Lyc3NCVkeHUh?=
MRK-nu-1 M3zZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLJTWM2OD15Mz60O|A2KM7:TR?= NIjUb5lUSU6JRWK=
D-247MG NWnxS25ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr3U2pKSzVyPUezMlU1PDJizszN Mom1V2FPT0WU
OCI-AML2 M4TTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzpUJNKSzVyPUe2Mlk{PjlizszN M3:zVnNCVkeHUh?=
LP-1 NXn2TI5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LHbmlEPTB;OEKuPFc{OSEQvF2= M4P6ZnNCVkeHUh?=
HCC1599 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTh2LkK4N|ch|ryP NFLSWphUSU6JRWK=
KARPAS-45 NXHPWI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fSSGlEPTB;OESuOlk6OiEQvF2= NWryfpZNW0GQR1XS
BE-13 NFniTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLqTWM2OD17OT6wOFc4KM7:TR?= M2W0OnNCVkeHUh?=
GCIY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XEPWlEPTB;OUmuNFk2PCEQvF2= NH;hZ4FUSU6JRWK=
BV-173 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHITWM2OD1zMECuN|I2KM7:TR?= MkLHV2FPT0WU
LB2518-MEL MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFyMD63PFkh|ryP MYfTRW5ITVJ?
KS-1 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFyMT62N|kh|ryP M3;n[XNCVkeHUh?=
MOLT-16 NIDjPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFyND65PFYh|ryP NHLOfJhUSU6JRWK=
NCI-H1770 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33TWM2OD1zMEiuO|g1KM7:TR?= MmD4V2FPT0WU
NCI-H82 NF7kZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfDTWM2OD1zMUCuPVc3KM7:TR?= MofGV2FPT0WU
NCCIT NWLB[4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L5PWlEPTB;MUGyMlUzQSEQvF2= MYnTRW5ITVJ?
KALS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFzNT65OFEh|ryP NULiRYJ3W0GQR1XS
LB2241-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:5XGlEPTB;MUG2MlY4QSEQvF2= MmPTV2FPT0WU
HH MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO5[XdKSzVyPUGxO{4{QTVizszN MYnTRW5ITVJ?
HD-MY-Z MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P6PWlEPTB;MUG4MlQ5QCEQvF2= NWOxO4prW0GQR1XS
EB-3 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPuTWM2OD1zMkOuNFk1KM7:TR?= NFjHPHVUSU6JRWK=
BL-70 NVrOVVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnWNIdKSzVyPUGyN{4yOjdizszN NVjlNlZIW0GQR1XS
K-562 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PpTWlEPTB;MUK2MlI1PSEQvF2= NGKz[3BUSU6JRWK=
HT-144 NGHI[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q5fGlEPTB;MUOzMlE3PCEQvF2= NHPaSHVUSU6JRWK=
PF-382 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi3SHdoUUN3ME2xN|QvOzZzIN88US=> M3XQZ3NCVkeHUh?=
RPMI-8226 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XCVmlEPTB;MUO1MlA1PSEQvF2= NETMNWNUSU6JRWK=
NCI-H1355 NGjuZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF|NT61PFch|ryP NHvOOGJUSU6JRWK=
LXF-289 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF|OT63PFEh|ryP MnXPV2FPT0WU
NCI-H69 NUSweGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX62TGJsUUN3ME2xOFIvQTN{IN88US=> NFjPXmZUSU6JRWK=
SK-MEL-1 NGTGT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNNmlEPTB;MUS3MlE{KM7:TR?= MVrTRW5ITVJ?
KARPAS-299 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF2OT6xNkDPxE1? M2DQfHNCVkeHUh?=
GB-1 M{DqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3XdJJjUUN3ME2xOFkvOzJ{IN88US=> MoLDV2FPT0WU
CMK MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XTWWlEPTB;MUS5MlUyPSEQvF2= Mn7oV2FPT0WU
MPP-89 M372VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\qR3lKSzVyPUG1Ok4xOzVizszN NWf5WXkxW0GQR1XS
KU812 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF4MT65NFIh|ryP NEDi[XRUSU6JRWK=
REH MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmKyTWM2OD1zNkKuNVI2KM7:TR?= NIPkfVNUSU6JRWK=
NEC8 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn0SFZHUUN3ME2xOlUvODJ4IN88US=> MoWxV2FPT0WU
KP-N-YS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjUbJlKSzVyPUG2PE4{QTVizszN MYDTRW5ITVJ?
Ramos-2G6-4C10 NXTnb49JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXk[I1jUUN3ME2xOlkvQTF3IN88US=> MYLTRW5ITVJ?
Becker MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fMcmlEPTB;MUe0MlE5KM7:TR?= MWrTRW5ITVJ?
LB647-SCLC M3zjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fQdGlEPTB;MUe1Mlg1PSEQvF2= MUPTRW5ITVJ?
LU-139 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz0c4VtUUN3ME2xO|gvODF7IN88US=> NELN[I5USU6JRWK=
QIMR-WIL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3JemhuUUN3ME2xO|kvPjR4IN88US=> M3fUSHNCVkeHUh?=
NCI-H1395 NX;xToV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XkXGlEPTB;MUe5Mlk6PiEQvF2= MWLTRW5ITVJ?
NOMO-1 NVzibXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzlbVBKSzVyPUG4Nk45PSEQvF2= MXvTRW5ITVJ?
GI-ME-N MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37ZVmlEPTB;MUi3Mlk3QSEQvF2= MYnTRW5ITVJ?
KMS-12-PE M3TjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\PbZZKSzVyPUG4PU4zPzNizszN NIPPOIlUSU6JRWK=
Daudi MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCwc49KSzVyPUG5NU4yOjhizszN Mk\kV2FPT0WU
LB996-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7yZYZoUUN3ME2xPVEvPjl7IN88US=> M1O2R3NCVkeHUh?=
NCI-H2107 NXSyOHNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED1[mJKSzVyPUG5N{44OzlizszN MXrTRW5ITVJ?
SK-PN-DW M{LIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF7ND63NVkh|ryP NUnpSVdsW0GQR1XS
MC-CAR NUHM[JgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS3RZJ4UUN3ME2yNFIvOjV|IN88US=> NH;2fZRUSU6JRWK=
SNB75 M4G0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M122N2lEPTB;MkKxMlk1KM7:TR?= NXu1SWhnW0GQR1XS
ES4 NYX1SVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnSR2o2UUN3ME2yNlMvPzh|IN88US=> MmPQV2FPT0WU
KARPAS-422 M2nGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXewPYl4UUN3ME2yNlgvOzV{IN88US=> Mmn4V2FPT0WU
NCI-H1648 M3XYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnCTJRRUUN3ME2yNlkvPDh7IN88US=> NHfBVmhUSU6JRWK=
ES6 NEG5WnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ|OT60N{DPxE1? M2jjfXNCVkeHUh?=
KNS-81-FD MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXLTWM2OD1{NEGuNVk4KM7:TR?= M4qyWnNCVkeHUh?=
JAR NXXMXI5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\IcGlEPTB;MkW2MlIzPSEQvF2= NUjxOYZJW0GQR1XS
NB1 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17NOGlEPTB;Mk[wMlUyPiEQvF2= NH7B[pNUSU6JRWK=
D-336MG M3XneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLzTWM2OD1{NkCuOlk5KM7:TR?= M16yNXNCVkeHUh?=
BC-3 M3jtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SwZmlEPTB;Mk[1MlE4QCEQvF2= NH3V[2hUSU6JRWK=
HCC2218 NUm2e3RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ4Nj60NVUh|ryP NF3ibWhUSU6JRWK=
TE-9 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELIVWVKSzVyPUK2Ok43OjdizszN Mlv1V2FPT0WU
LB1047-RCC MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ4Nj63OVMh|ryP MXTTRW5ITVJ?
CTB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ4OT65O|Mh|ryP M{\oXnNCVkeHUh?=
NB7 NUXWbmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrX[mpvUUN3ME2yO|Eh|ryP NXjrNmgxW0GQR1XS
ST486 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjRbXBKSzVyPUK3O{41OTJizszN NHrTTFdUSU6JRWK=
HCC1187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ6Mj64NVEh|ryP NXTuUZlYW0GQR1XS
NCI-SNU-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP6O2NKSzVyPUK4OE4zPDhizszN NXPiZnl1W0GQR1XS
COR-L279 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjITWM2OD1{OUGuOVg1KM7:TR?= NECwO|JUSU6JRWK=
ES8 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTlTWM2OD1{OUSuNVgzKM7:TR?= NEnXcoVUSU6JRWK=
U-698-M M{D2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnnXmNEUUN3ME2yPVgvOjR|IN88US=> NX2zcYMyW0GQR1XS
HEL NFHnZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LIfWlEPTB;M{C5MlE1QSEQvF2= MmWwV2FPT0WU
KINGS-1 NU\ZN2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD1|MUCuOlc1KM7:TR?= NFG4b4RUSU6JRWK=
KY821 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyzOWVKSzVyPUOzOk42QTVizszN NEnxPYRUSU6JRWK=
MZ1-PC NGHxVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrhToJKSzVyPUO0OU43OThizszN MlTNV2FPT0WU
LS-411N NYflXmF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHkbpFMUUN3ME2zOVQvPjZizszN Ml61V2FPT0WU
SIG-M5 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M360emlEPTB;M{W5Mlc5OiEQvF2= NYrPS2NYW0GQR1XS
HT MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPaTWM2OD1|NkeuO|EyKM7:TR?= M{XVO3NCVkeHUh?=
HC-1 NE\0bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK1TWM2OD1|NkeuO|g4KM7:TR?= NIC2cFdUSU6JRWK=
NCI-H1694 M1HncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN5Mj65N|Qh|ryP NUnnOGg1W0GQR1XS
BB65-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljaTWM2OD1|N{[uNlQ2KM7:TR?= NF[0VJNUSU6JRWK=
HAL-01 NXThbZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN5OT64N|gh|ryP M3HVbHNCVkeHUh?=
ARH-77 M1fEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17sbWlEPTB;M{m0MlAxQCEQvF2= NW\qUXVpW0GQR1XS
MZ7-mel NHLjdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDiU41yUUN3ME2zPVcvOjN|IN88US=> MnHNV2FPT0WU
SIMA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnyfGk6UUN3ME20NFMvQTN|IN88US=> MmXQV2FPT0WU
DG-75 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Jb2lEPTB;NEG1MlY6QCEQvF2= NWjuS2R7W0GQR1XS
HUTU-80 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG1TWM2OD12MUmuNVg2KM7:TR?= NFTBb|RUSU6JRWK=
KNS-42 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDiXXBKSzVyPUSyOU45OTVizszN NGewTWVUSU6JRWK=
SH-4 NXnzUZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfPUnptUUN3ME20NlcvPTZ3IN88US=> MkPOV2FPT0WU
L-540 NUHXS4s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe5TnRKSzVyPUSzNU4xOzFizszN M{\zcXNCVkeHUh?=
NB10 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;FTWM2OD12NEGuNlM1KM7:TR?= NFHqNYNUSU6JRWK=
ES1 M1jDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfqSJdKSzVyPUS1Nk44PTNizszN NYixeFRFW0GQR1XS
KMOE-2 NGfFZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfQTWM2OD12NU[uO|EyKM7:TR?= M3PQenNCVkeHUh?=
MC116 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M123SWlEPTB;NEW4MlEyPiEQvF2= NWDXbGZtW0GQR1XS
RCC10RGB M4XNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTR4MD6wNFUh|ryP Mme4V2FPT0WU
RL95-2 NU[2cIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\5T2lEPTB;NE[wMlI{PyEQvF2= M3XoT3NCVkeHUh?=
Raji NX3ZeVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3OOlRKSzVyPUS2PE4yPDNizszN M1T0cHNCVkeHUh?=
CAS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR5Mj6wO|Mh|ryP NFvhNVRUSU6JRWK=
Calu-6 M3f0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzuTZdKSzVyPUS3OU4zPjVizszN MUfTRW5ITVJ?
KG-1 NXPTcJNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXrTWM2OD12N{iuOFQh|ryP MnzBV2FPT0WU
LB771-HNC NFy2eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHsOHYyUUN3ME20PFIvOjN{IN88US=> MV\TRW5ITVJ?
ACN MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Udlh6UUN3ME20PVMvPTl7IN88US=> M33YdnNCVkeHUh?=
KM12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR7Nj61PFkh|ryP MWnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products4

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID